Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Anti-VEGFR2 CAR CD8 lymphocytes |
| Synonyms | |
| Therapy Description |
Anti-VEGFR2 CAR CD8 lymphocytes consists of patient's own T-lymphocytes transduced with a recombinant retroviral vector encoding a chimeric T cell receptor specific for KDR (VEGFR2), expanded and reintroduced into the patient. The cells bind to and subsequently lyse VEGFR2-expressing cells (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Anti-VEGFR2 CAR CD8 lymphocytes | VEGFR2 Immune Cell Therapy 1 | Anti-VEGFR2 CAR CD8 lymphocytes consists of patient's own T-lymphocytes transduced with a recombinant retroviral vector encoding a chimeric T cell receptor specific for KDR (VEGFR2), expanded and reintroduced into the patient. The cells bind to and subsequently lyse VEGFR2-expressing cells (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT01218867 | Phase Ib/II | Anti-VEGFR2 CAR CD8 lymphocytes Cyclophosphamide Fludarabine Aldesleukin | Treating Metastatic Cancer With Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes | Terminated | USA | 0 |